While traditionally used for Clostridioides difficile infection, preclinical studies demonstrate FMT’s capacity to remodel gut ecosystems, reduce Aβ burden by 40–60% in AD mouse models [14], and reverse tau hyperphosphorylation (p-tau) [15]. Here, MAPT is linked to Alzheimer disease.